Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Pancreatic Islet Cell Tumors

Review the pancreatic islet cell tumors treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-10 of 10

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Status: Active
Location: 440 locations
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Status: Active
Location: 25 locations
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Status: Active
Location: 8 locations
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Status: Active
Location: 7 locations
ESK981 for the Treatment of Patients with Select Advanced Solid Tumors
Status: Active
Location: 3 locations
Lenvatinib and Pembrolizumab for the Treatment of Locally Advanced or Unresectable Well Differentiated G3 Neuroendocrine Tumors
Status: Active
Location: University of California San Francisco, San Francisco, California
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
177Lu-DOTATATE and Fulvestrant for the Treatment of Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients with Progressing Metastatic Neuroendocrine Carcinomas
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York